Merz Aesthetics

Merz Aesthetics is the medical-aesthetics business within Merz Group and commercializes Xeomin in aesthetic markets. Xeomin is a botulinum toxin type A medicine with the nonproprietary name incobotulinumtoxinA. Merz Aesthetics also has a wider portfolio of injectables, devices, and skin care products. (Merz Aesthetics company and China launch announcement 🔗)
Merz Aesthetics is not the name for every Merz entity connected to Xeomin. The wider family-owned Merz Group also includes Merz Therapeutics. The U.S. FDA lists Merz Pharmaceuticals GmbH as the Xeomin biologics-license applicant, and the current U.S. prescribing information names it as manufacturer. These roles matter because Xeomin appears in both aesthetic and therapeutic contexts, while approved uses and warnings remain product- and market-specific. (FDA Purple Book 🔗; U.S. prescribing information, revised June 2026 🔗)
Quick Answers
Section titled “Quick Answers”| Question | Short answer |
|---|---|
| Who makes Xeomin? | The current U.S. label names Merz Pharmaceuticals GmbH as manufacturer. It names Merz Pharmaceuticals, LLC and Merz North America, Inc. as distributors. |
| What is Merz Aesthetics? | Merz Aesthetics is the medical-aesthetics business within the wider Merz Group. It is not a replacement name for Merz Therapeutics or the product’s named manufacturer. |
| What is incobotulinumtoxinA? | IncobotulinumtoxinA is the nonproprietary name used for Xeomin. |
| Is Xeomin the same as Botox or Dysport? | No. Xeomin, Botox, and Dysport are separate botulinum toxin type A products with product-specific labels and potency units. |
| Does Xeomin’s formulation prove it is better? | No. Formulation is a product-identity and handling point; it should not be turned into a broad claim of superior safety, strength, duration, or effectiveness without product-specific evidence. |
| Why do Merz Aesthetics and Merz Therapeutics both matter? | Merz Aesthetics presents Xeomin in aesthetic markets; Merz Therapeutics communicates therapeutic uses. Neither business name replaces the product’s regulatory label. |
Reference Card
Section titled “Reference Card”| Field | Reference point |
|---|---|
| Company | Merz Aesthetics |
| Parent company | Merz Group (Merz Aesthetics company overview 🔗) |
| Official website | Merz Aesthetics 🔗 |
| Corporate headquarters | Raleigh, North Carolina, United States (Merz Aesthetics locations 🔗) |
| Parent ownership status | Family-owned company (About Merz 🔗) |
| Aesthetic business | Merz Aesthetics |
| Therapeutic business | Merz Therapeutics |
| Manufacturer named in U.S. prescribing information | Merz Pharmaceuticals GmbH (DailyMed: Xeomin label 🔗) |
| U.S. biologics-license applicant | Merz Pharmaceuticals GmbH (FDA Purple Book 🔗) |
| U.S. label distributors | Merz Pharmaceuticals, LLC; Merz North America, Inc. (DailyMed: Xeomin label 🔗) |
| Core toxin relationship | Xeomin (incobotulinumtoxinA), a botulinum toxin type A product |
| Main brand node | Xeomin |
| Product identity | Xeomin is incobotulinumtoxinA |
Related People
Section titled “Related People”| Person | Why the relationship matters |
|---|---|
| Philip Burchard | Chief Executive Officer of Merz Group 🔗, separate from Merz Aesthetics and Merz Therapeutics business-unit leadership. |
| Bob Rhatigan | Chief Executive Officer of Merz Aesthetics 🔗, connecting the current aesthetics business to Xeomin commercialization and its wider portfolio. |
| Jürgen Frevert, Ph.D. | Botulinum toxin researcher associated with NT201 development and Merz product-science history, distinct from current group and business-unit leadership. |
Xeomin Company And Product Identity
Section titled “Xeomin Company And Product Identity”Xeomin connects Merz’s aesthetic and therapeutic businesses through the same incobotulinumtoxinA product identity. Different business names describe commercial responsibilities; they do not by themselves identify a different medicine or its physical manufacturer.
A formulation distinction can be relevant to product identity, storage discussion, or immunogenicity interpretation. It should not be converted into broad claims that Xeomin is safer, longer-lasting, stronger, or clinically superior without strong product-specific support.
Merz Aesthetics, Merz Group, And Merz Therapeutics
Section titled “Merz Aesthetics, Merz Group, And Merz Therapeutics”Merz’s current business overview 🔗 presents Merz Aesthetics, Merz Therapeutics, and Merz Lifecare as distinct areas within the wider group. Xeomin may appear through aesthetic or therapeutic Merz channels depending on the market, indication, and audience.
That structure should not be mistaken for separate toxin products. The company context may vary, but Xeomin remains the incobotulinumtoxinA product node that should be interpreted through product-specific information.
| Merz name readers may encounter | How to read it |
|---|---|
| Merz Group | Broad parent-company context behind Merz Aesthetics, Merz Therapeutics, and other businesses. |
| Merz Aesthetics | Medical-aesthetics business where Xeomin may appear alongside non-toxin aesthetic products. |
| Merz Therapeutics | Therapeutic Merz context for neurological and medical uses. |
| Merz Pharmaceuticals GmbH | Applicant in the FDA Purple Book and manufacturer identified in the current U.S. Xeomin label. |
| Merz Pharmaceuticals, LLC and Merz North America, Inc. | Distributors named in the current U.S. label; distribution does not establish physical manufacture. |
Current U.S. Label Context
Section titled “Current U.S. Label Context”The U.S. Xeomin prescribing information revised June 2026 🔗 covers both aesthetic and therapeutic uses. It lists temporary improvement of moderate to severe glabellar lines, horizontal forehead lines, and lateral canthal lines in adults, alongside chronic sialorrhea in patients aged 2 years and older, upper limb spasticity in patients aged 2 years and older, and cervical dystonia and blepharospasm in adults. The June 2026 label change expanded pediatric upper limb spasticity to include children with cerebral palsy; it was an expansion of an existing indication, not Xeomin’s first U.S. approval. (Merz Therapeutics announcement 🔗; FDA Purple Book 🔗)
The U.S. label’s indication list does not establish approval in other countries. It also retains a boxed warning about distant spread of toxin effect and states that Xeomin potency units cannot be compared with or converted into units of other botulinum toxin products.
Regional Launches And Commercial Partnerships
Section titled “Regional Launches And Commercial Partnerships”On December 16, 2025, Merz Aesthetics announced the launch of Xeomin and Radiesse in China. This was a regional commercialization milestone for its aesthetics portfolio; the announcement does not establish that Chinese indications match those in the United States. (Merz Aesthetics China launch announcement 🔗)
Merz Therapeutics also uses local commercial partners. Its Brazil partnership announcement states that Grünenthal would take over Xeomin commercialization responsibilities from Biolab Farmacêutica effective July 1, 2026. The change concerns local commercialization, not the manufacturer named in the U.S. label or a transfer of Merz Group ownership. (Merz Therapeutics: Grünenthal partnership in Brazil 🔗)
European Pediatric Label Expansion
Section titled “European Pediatric Label Expansion”On September 17, 2026, Merz Therapeutics announced EU/EEA approval of Xeomin for symptomatic treatment of spasticity associated with pes equinus in children and adolescents with cerebral palsy aged 2–17 years, including those who can walk and those who cannot. Pes equinus describes a downward-pointing foot position associated with tight calf muscles. (Merz Therapeutics EU/EEA approval announcement 🔗)
This European announcement concerns lower limb spasticity associated with pes equinus. It is distinct from the June 2026 U.S. expansion of pediatric upper limb spasticity to include cerebral palsy. The company announcement describes the European milestone; individual national product information defines the applicable local label.
Investigational Uses And Evidence Limits
Section titled “Investigational Uses And Evidence Limits”On October 15, 2026, Merz Therapeutics announced completion of recruitment in two Phase III trials investigating Xeomin for migraine prevention. Recruitment completion is a study milestone; it does not establish positive results or regulatory approval for migraine prevention. (Merz Therapeutics Phase III recruitment announcement 🔗)
On October 26, 2026, Merz Therapeutics presented Phase 2 PaiNT findings in peripheral neuropathic pain, or pain caused by damage to nerves outside the brain and spinal cord. The company reported exploratory findings favoring incobotulinumtoxinA in the postherpetic neuralgia subgroup, but the trial’s combined-population primary endpoint did not significantly separate from placebo. The announcement states that incobotulinumtoxinA is not approved for peripheral neuropathic pain and that safety and efficacy for that use have not been established. Subgroup findings do not establish overall trial success or a new approved indication. (Merz Therapeutics PaiNT announcement 🔗)
Market Interpretation
Section titled “Market Interpretation”Merz adds a distinct reference point to the major type A comparison set. Botox, Dysport, and Xeomin are often grouped together as established global brands, while Jeuveau, Daxxify, and Letybo add newer U.S. aesthetic-market comparison points.
That grouping helps readers navigate the market, but the products remain separate medicines. Units, approved indications, preparation, and warnings are defined by product-specific labels.
Label and Comparison Limits
Section titled “Label and Comparison Limits”Xeomin claims should be anchored to current prescribing information and the relevant market. Regional labels may differ, and a formulation shorthand should not replace local regulatory records.
Botulinum toxin type A provides the shared biology. Botulinum toxin explains why products in the same family still use product-specific potency systems.

